Access Denied

Join ICON Biotech at OCT Southern California on 15–16 September at the Hyatt Regency La Jolla at Aventine, San Diego. Visit our team at Booth \#26. We welcome the opportunity to connect with biotech sponsors to discuss ...

Before restricting a trial to “marker‑positive” patients, developers must ask whether they’re excluding people who could still benefit, and potentially shrinking their future label. ICON’s Peter Schueler and Jack Martin ...

Robust statistical analysis plans are essential for the appropriate reporting of clinical trials and the reproducibility of findings, particularly for cell and cell-based gene therapies, where treatment pathways and outc...

Shift the publishing odds to your favour. Journals & Congresses offers comparable rejection rate insights. Review rejection rates by journal to better target the right fit for your submission. Check out our interactive d...

Clinical trials are becoming more complex, but complexity does not have to mean inefficiency. As study demands increase, sponsors need better visibility, stronger site engagement and operational intelligence that suppor...

The landscape for obesity therapeutics is expanding to address critical limitations of first-gen GLP-1s. There are now over 100 active obesity-specific clinical trials worldwide, with more than 60 in phase II/III stages....

ICON invites you to connect with our biomarker experts at WorldCDx. From biomarker discovery to diagnostic readiness we deliver integrated precision medicine solutions for clinical development. We work across all major p...

We're proud to share that ICON has been named one of TIME's World's Best Companies for the fourth consecutive year. This recognition reflects the expertise, commitment, and collaboration of our colleagues around the wor...

Early intervention is the most promising path forward for MASLD, and extremely difficult to execute. Without reliable methods for identifying biologically high-risk patients before symptoms emerge, early-intervention tri...

How do you accelerate enrolment without sacrificing retention? As obesity trials grow more complex, sponsors must navigate increasing competition for treatment-naïve participants, evolving endpoints and differentiated t...

For regulatory agencies to evaluate the benefits of a new treatment and validate labeling claims, sponsors need a COA strategy that is fit for purpose and supported by appropriate evidence. Yet COA decisions are often ...

More than 1,500 AI-enabled medical devices have now received FDA authorisation, with most approved in the last decade. As AI technologies advance from detection tools to systems that support diagnosis and treatment decis...